![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION
Danielle Alberti Memorial Centre for Diabetes Complications, Baker Medical Research Institute, Melbourne, Victoria, Australia
Tubular dysfunction is an important early manifestation of diabetic nephropathy. Reduced renal expression of organic cation transporters (OCTs) potentially contributes to impaired cation clearance in diabetes. This study examines the role of advanced glycation end-products (AGEs) in mediating these changes. Experimental diabetes was induced with streptozotocin (55 mg/kg). Rats were randomly treated with the AGE inhibitor aminoguanidine for 32 weeks. In a second protocol, diabetic rats were followed with and without low-dose insulin therapy (2 U/day) for 4 weeks. Expression of OCTs was determined by real-time RT-PCR (reverse transcription-polymerase chain reaction) and Western blotting. As a marker of cation transport, the fractional clearance of endogenous N-methylnicotinamide (NMN) was determined by high-performance liquid chromatography. Both short- and long-term diabetes was associated with reduced gene and protein expression of the three renal OCT isotypes. This was associated with a reduction in the fractional clearance of NMN compared with control animals by over 50%. These changes correlated with the accumulation of renal and plasma AGEs. Treatment with the AGE inhibitor aminoguanidine restored the expression of OCT-2 and OCT-3 in diabetic animals and normalized renal NMN clearance. NMN clearance was also improved in diabetic animals receiving low-dose insulin, correlating with a reduction in AGEs and improvement in effective renal plasma flow. These studies demonstrate an early impairment of expression of OCTs and cation clearance associated with diabetes. These changes correlate with the accumulation of AGEs and may be partly attenuated by an AGE inhibitor, implicating a role for AGEs in organic cation transport.
Address correspondence to: Dr. Merlin C Thomas, Baker Medical Research Institute, Baker Medical Research Institute, P.O. Box 6492, Melbourne, VIC 8008, Australia. E-mail: mthomas{at}baker.edu.au
This article has been cited by other articles:
![]() |
T. Matsuzaki, T. Morisaki, W. Sugimoto, K. Yokoo, D. Sato, H. Nonoguchi, K. Tomita, T. Terada, K.-i. Inui, A. Hamada, et al. Altered Pharmacokinetics of Cationic Drugs Caused by Down-Regulation of Renal Rat Organic Cation Transporter 2 (Slc22a2) and Rat Multidrug and Toxin Extrusion 1 (Slc47a1) in Ischemia/Reperfusion-Induced Acute Kidney Injury Drug Metab. Dispos., April 1, 2008; 36(4): 649 - 654. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Pelis, Y. Dangprapai, T. M. Wunz, and S. H. Wright Inorganic mercury interacts with cysteine residues (C451 and C474) of hOCT2 to reduce its transport activity Am J Physiol Renal Physiol, May 1, 2007; 292(5): F1583 - F1591. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Pelis, X. Zhang, Y. Dangprapai, and S. H. Wright Cysteine Accessibility in the Hydrophilic Cleft of Human Organic Cation Transporter 2 J. Biol. Chem., November 17, 2006; 281(46): 35272 - 35280. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Ciarimboli, T. Ludwig, D. Lang, H. Pavenstadt, H. Koepsell, H.-J. Piechota, J. Haier, U. Jaehde, J. Zisowsky, and E. Schlatter Cisplatin Nephrotoxicity Is Critically Mediated via the Human Organic Cation Transporter 2 Am. J. Pathol., December 1, 2005; 167(6): 1477 - 1484. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Y. Chow, D. J. Nikolic-Paterson, E. Ozols, R. C. Atkins, and G. H. Tesch Intercellular Adhesion Molecule-1 Deficiency Is Protective against Nephropathy in Type 2 Diabetic db/db Mice J. Am. Soc. Nephrol., June 1, 2005; 16(6): 1711 - 1722. [Abstract] [Full Text] [PDF] |
||||